Will Corcept (CORT) Beat Estimates Again in Its Next Earnings Report?

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Corcept Therapeutics (CORT) , which belongs to the Zacks Medical - Drugs industry.When looking at the last two reports, this drug developer has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 46.97%, on average, in the last two quarters.For the last reported quarter, Corcept came out with earnings of $0.28 per sh ...